HUNTINGTON MEDICAL RESEARCH INSTITUTES
🇺🇸United States
Clinical Trials
4
Active:0
Completed:2
Trial Phases
2 Phases
Phase 2:2
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 4
1 (33.3%)Multimodal Approach to Testing the Acute Effects of Mild Traumatic Brain Injury (mTBI)
Completed
- Conditions
- Concussion, Mild
- First Posted Date
- 2014-02-24
- Last Posted Date
- 2017-11-08
- Lead Sponsor
- Huntington Medical Research Institutes
- Target Recruit Count
- 44
- Registration Number
- NCT02069613
- Locations
- 🇺🇸
Huntington Medical Research Institutes, Pasadena, California, United States
🇺🇸HMRI, Pasadena, California, United States
🇺🇸Molecular Neurology Program, Pasadena, California, United States
Minocycline in Patients With Alzheimer's Disease
Phase 2
Completed
- Conditions
- Mild Cognitive ImpairmentAlzheimer's Disease
- Interventions
- First Posted Date
- 2011-11-01
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Huntington Medical Research Institutes
- Target Recruit Count
- 13
- Registration Number
- NCT01463384
- Locations
- 🇺🇸
Huntington Medical Research Institutes, Pasadena, California, United States
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2010-06-10
- Lead Sponsor
- Huntington Medical Research Institutes
- Target Recruit Count
- 40
- Registration Number
- NCT00941642
- Locations
- 🇺🇸
HMRI - Liver Center, Pasadena, California, United States
A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis B
Phase 2
- Conditions
- Hepatitis B
- Interventions
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2010-10-21
- Lead Sponsor
- Huntington Medical Research Institutes
- Target Recruit Count
- 30
- Registration Number
- NCT00753467
- Locations
- 🇺🇸
Huntington Medical Research Institutes, Pasadena, California, United States
News
Empagliflozin Significantly Reduces Stroke Size in Preclinical Studies
Researchers found that empagliflozin (EMPA), an antidiabetic drug, dramatically reduced the size of cerebral infarctions in preclinical stroke models.